Logie 2010.

Study characteristics
Methods	Study design: randomized controlled trial Study grouping: 2 groups, monoprophylaxis
Participants	Baseline characteristics Alizapride Assessed for eligibility (n): ‐ Enrolled (n): ‐ Randomized (n): NA Received treatment (n): NA Analysed (n): 73 Age (mean ± SD, median (IQR), median (range)): 42.3 ± 14.3 Weight (mean ± SD, median (IQR), median (range)): 66 ± 13 BMI (mean ± SD, median (IQR), median (range)): 24.8 ± 5.0 ASA I/II/III/IV (n): NA Gender (female in %): 100 Non‐smoker (%): NA History of PONV/motion sickness (%): NA Type of general anaesthesia: balanced anaesthesia (sevoflurane, sufentanil) Duration of anaesthesia or surgery (in min; as mean or median): 112 Use of perioperative opioids (if yes, which?): intraoperative sufentanil, piritramide as postoperative rescue analgesics Type of surgery: laparoscopic gynaecological surgery Placebo Assessed for eligibility (n): ‐ Enrolled (n): ‐ Randomized (n): NA Received treatment (n): NA Analysed (n): 53 Age (mean ± SD, median (IQR), median (range)): 41.9 ± 14.2 Weight (mean ± SD, median (IQR), median (range)): 65 ± 12 BMI (mean ± SD, median (IQR), median (range)): 23.5 ± 5.0 ASA I/II/III/IV (n): NA Gender (female in %): 100 Non‐smoker (%): NA History of PONV/motion sickness (%): NA Type of general anaesthesia: balanced anaesthesia (sevoflurane, sufentanil) Duration of anaesthesia or surgery (in min; as mean or median): 120 Use of perioperative opioids (if yes, which?): intraoperative sufentanil, piritramide as postoperative rescue analgesics Type of surgery: laparoscopic gynaecological surgery Included criteria: adult women scheduled for elective laparoscopic gynaecological surgery Excluded criteria: NA Pretreatment: baseline characteristics (age, weight): no; (ASA): unclear. Potential effect modifiers (gender, duration of anaesthesia): no; (history of PONV/motion sickness, non‐smoker, perioperative opioids): unclear
Interventions	Intervention characteristics Alizapride Dose: 100 mg Time point of administration: 30 minutes before end of the operation Route of administration: IV Rescue antiemetics (if yes, which?): first‐line droperidol 1.25 + dexamethasone 5 mg, second‐line ondansetron 4 mg + alizapride 100 mg Placebo Dose: saline Time point of administration: 30 minutes before end of the operation Route of administration: IV Rescue antiemetics (if yes, which?): first‐line droperidol 1.25 + dexamethasone 5 mg, second‐line ondansetron 4 mg + alizapride 100 mg
Outcomes	Vomiting (0 to 24 hours) Outcome type: dichotomous outcome
Identification	Sponsorship source: NA Country: Belgium Setting: NA Author's name: Nathalie Logie Institution: NA Email: NA Address: NA Duration of study: NA Language: English Study's primary outcome: NA Trial registry number: NA
Notes	None
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Judgement comment: quote: "randomised". No further information on sequence generation provided
Allocation concealment (selection bias)	Unclear risk	Judgement comment: no statement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Judgement comment: insufficient information on blinding ("double‐blind")
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Judgement comment: insufficient information on blinding ("double‐blind")
Incomplete outcome data (attrition bias) All outcomes	Low risk	Judgement comment: no missing outcome data
Selective reporting (reporting bias)	Unclear risk	Judgement comment: no reference to a study protocol or trial registry number reported
Other bias	Unclear risk	Judgement comment: baseline characteristics (age, weight): no; (ASA): unclear. Potential effect modifiers (gender, duration of anaesthesia): no; (history of PONV/motion sickness, non‐smoker, perioperative opioids): unclear